Drug Profile
Chymotrypsinogen/trypsinogen - Propanc Biopharma
Alternative Names: PRP; PRP-DCP; PRP-Injection™Latest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Propanc Health Group Corporation
- Developer Propanc Biopharma
- Class Antineoplastics; Enzyme precursors; Serine endopeptidases
- Mechanism of Action Angiogenesis inhibitors; Cell differentiation stimulants; PAR-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Clinical Phase Unknown Cancer
- Preclinical Colorectal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 02 Jan 2024 Propanc Biopharma plans a first-in-human phase Ib trial for Solid tumours (Late-stage disease) in Australia, Europe and United Kingdom in 2024
- 07 Nov 2023 Pharmacodynamics data from a preclinical study in Pancreatic cancer released by Propanc Biopharma
- 25 May 2023 Chymotrypsinogen/trypsinogen - Propanc is available for licensing as of 25 May 2023. https://www.propanc.com/